The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rozanov I.D.

S.P. Botkin City Clinical Hospital

Lebedev S.S.

S.P. Botkin City Clinical Hospital

Grekov D.N.

S.P. Botkin City Clinical Hospital

Yakusheva T.A.

S.P. Botkin City Clinical Hospital

Balkanov A.S.

M.F. Vladimirsky Regional Research Clinical Institute

Drug therapy for brain glioblastoma

Authors:

Rozanov I.D., Lebedev S.S., Grekov D.N., Yakusheva T.A., Balkanov A.S.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2023;12(5): 65‑70

DOI: 10.17116/onkolog20231205165

Read: 4820 times

Download PDF (RU)
Contact the author
Table of contents

DRUG THERAPY FOR BRAIN GLIOBLASTOMA
DRUG THERAPY FOR BRAIN GLIOBLASTOMA

To cite this article:

Rozanov ID, Lebedev SS, Grekov DN, Yakusheva TA, Balkanov AS. Drug therapy for brain glioblastoma. P.A. Herzen Journal of Oncology. 2023;12(5):65‑70. (In Russ.)
https://doi.org/10.17116/onkolog20231205165

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effi­cacy of chemoimmunotargeted therapy in patients with adva­nced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Onco­logy. 2025;(3):63-70
Refractory/relapsed primary mediastinal large B-cell lymphoma: a changing para­digm for drug therapy. P.A. Herzen Journal of Onco­logy. 2025;(4):107-116
Prolactin-secreting pituitary carcinomas with intra- and extracranial meta­stasis: case report and review. Burdenko's Journal of Neurosurgery. 2025;(1):83-93
Clinical and Ultrasound Semiotics of Vari­cose Vein Recu­rrence. Journal of Venous Diso­rders. 2025;(1):28-36
Application of T-cells with chimeric anti­gen rece­ptor in the treatment of refractory autoimmune diseases. Russian Journal of Preventive Medi­cine. 2025;(7):106-110
Extracranial meta­stasis of WHO Grade I benign meni­ngioma: a clinical case and lite­rature review. Burdenko's Journal of Neurosurgery. 2025;(4):106-111
The impact of combined immu­notherapy on the cellular composition of the tumor microenvironment in patients with gastric carcinoma. Russian Journal of Archive of Pathology. 2025;(4):24-30
Treatment of cancer in tubu­lar villous colo­rectal adenomas. Piro­gov Russian Journal of Surgery. 2025;(9):29-35
Inva­sive Treatment of Recu­rrent Vari­cose Veins in Patients with Femo­ral Vein Inco­mpetence. Journal of Venous Diso­rders. 2025;(3):156-163
Pathology features of recu­rrent meni­ngioma. Russian Journal of Archive of Pathology. 2025;(5):28-35
Abstract:

Primary glioblastoma (PGB), the most frequently detected malignant glioma of the brain, is diagnosed in 45% of cases. The generally accepted methods of treating PGB are a combination of surgical, radiation and drug therapies. The prognosis of survival in PGB is poor: the 5-year survival rate does not exceed 6—22%. The paper discusses in detail the current principles and algorithms for prescribing drug therapy for PGB and its recurrence, the promising areas for using chemotherapeutic, targeted, and immune therapies for this cancer.

Keywords:

brain glioblastoma
recurrence
temozolomide
adjuvant chemoradiotherapy
immunotherapy

Authors:

Rozanov I.D.

S.P. Botkin City Clinical Hospital

Lebedev S.S.

S.P. Botkin City Clinical Hospital

Grekov D.N.

S.P. Botkin City Clinical Hospital

Yakusheva T.A.

S.P. Botkin City Clinical Hospital

Balkanov A.S.

M.F. Vladimirsky Regional Research Clinical Institute

Received:

16.01.2023

Accepted:

22.01.2023

Close metadata

References:

  1. Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381-397.  https://doi.org/10.1016/B978-0-12-802997-8.00023-2
  2. Amirian ES, Armstrong GN, Zhou R, Lau CC, Claus EB, Barnholtz-Sloan JS, Il’yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, et al. The glioma international case-control study: a report from the genetic epidemiology of glioma international consortium. Am J Epidemiol. 2016;183(2):85-91.  https://doi.org/10.1093/aje/kwv235
  3. Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4(9):1254-1262. https://doi.org/10.1001/jamaoncol.2018.1789
  4. Nenning KH, Furtner J, Kiesel B, Schwartz E, Roetzer T, Fortelny N, Bock C, Grisold A, Marko M, Leutmezer F, et al. Distributed changes of the functional connectome in patients with glioblastoma. Sci Rep. 2020;10(1):18312. https://doi.org/10.1038/s41598-020-74726-1
  5. Vikhrova NB, Kalaeva DB, Postnov AA, Khokhlova EV, Konakova TA, Batalov AI, Pogosbekyan EL, Pronin IN. Dinamicheskaya PET/KT s 11S-metioninom v differentsial’noi diagnostike glial’nykh opukholei golovnogo mozga. Voprosy Neirokhirurgii im. N.N. Burdenko. 2021;85(3):5-13. (In Russ.). https://doi.org/10.17116/neiro2021850315
  6. Schupper AJ, Hadjipanayis C. Use of intraoperative fluorophores. Neurosurg Clin N Am. 2021;32(1):55-64.  https://doi.org/10.1016/j.nec.2020.08.001
  7. Watts C, Sanai N. Surgical approaches for the gliomas. Handb Clin Neurol. 2016;134:51-69.  https://doi.org/10.1016/B978-0-12-802997-8.00004-9
  8. Altwairgi AK, Raja S, Manzoor M, Aldandan S, Alsaeed E, Balbaid A, Alhussain H, Orz Y, Lary A, Alsharm AA. Management and treatment recommendations for World Health Organization Grade III and IV gliomas. Int J Health Sci (Qassim). 2017;11(3):54-62. 
  9. Randolph DM 2nd, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, et al. Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Clin Neurol Neurosurg. 2016;151:73-78.  https://doi.org/10.1016/j.clineuro.2016.10.012
  10. Fletcher-Sananikone E, Kanji S, Tomimatsu N, Di Cristofaro LFM, Kollipara RK, Saha D, Floyd JR, Sung P, Hromas R, Burns TC, et al. Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence. Cancer Res. 2021;81(23):5935-5947. https://doi.org/10.1158/0008-5472.CAN-21-0752
  11. Dzikowski L, Mirzaei R, Sarkar S, Kumar M, Bose P, Bellail A, Hao C, Yong VW. Fibrinogen in the glioblastoma microenvironment contributes to the invasiveness of brain tumor-initiating cells. Brain Pathol. 2021;31(5):e12947. https://doi.org/10.1111/bpa.12947
  12. Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63-82.  https://doi.org/10.1016/j.pharmthera.2015.05.005
  13. Szopa W, Burley TA, Kramer-Marek G, Kaspera W. Diagnostic and therapeutic biomarkers in glioblastoma: Current status and future perspectives. Biomed Res Int. 2017;2017:8013575. https://doi.org/10.1155/2017/8013575
  14. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073-1113. https://doi.org/10.1093/neuonc/noaa106
  15. Joo JD, Kim H, Kim YH, Han JH, Kim CY. Validation of the effectiveness and safety of temozolomide during and after radiotherapy for newly diagnosed glioblastomas: 10-year experience of a single institution. J Korean Med Sci. 2015;30(11):1597-1603. https://doi.org/10.3346/jkms.2015.30.11.1597
  16. Hanna C, Lawrie TA, Rogozińska E, Kernohan A, Jefferies S, Bulbeck H, Ali UM, Robinson T, Grant R. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev. 2020;3(3):CD013261. https://doi.org/10.1002/14651858.CD013261.pub2
  17. Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S. Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev. 2018;19(9):2613-2617. https://doi.org/10.22034/APJCP.2018.19.9.2613
  18. Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9(3):324.  https://doi.org/10.3390/biomedicines9030324
  19. Straube C, Kessel KA, Antoni S, Gempt J, Meyer B, Schlegel J, Schmidt-Graf F, Combs SE. A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma. Radiat Oncol. 2020;15(1):97.  https://doi.org/10.1186/s13014-020-01549-9
  20. Zorman MJ, Webb P, Nixon M, Sravanam S, Honeyman S, Nandhabalan M, Apostolopoulos V, Stacey R, Hobbs C, Plaha P. Surgical and oncological score to estimate the survival benefit of resection and chemoradiotherapy in elderly (≥70 years) glioblastoma patients: a preliminary analysis. Neurooncol Adv. 2022;4(1):vdac007. https://doi.org/10.1093/noajnl/vdac007
  21. Weller M, Steinbach JP, Wick W. Temozolomide: a milestone in the pharmacotherapy of brain tumors. Future Oncol. 2005;1(6):747-754.  https://doi.org/10.2217/14796694.1.6.747
  22. Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2020;22(5):684-693.  https://doi.org/10.1093/neuonc/noz222
  23. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, et el.; Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-926.  https://doi.org/10.1016/S1470-2045(12)70265-6
  24. Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, et al.; Trial Investigators. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027-1037. https://doi.org/10.1056/NEJMoa1611977
  25. Arulananda S, Lynam J, Sem Liew M, Wada M, Cher L, Gan HK. Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients. Intern Med J. 2018;48(10):1206-1214. https://doi.org/10.1111/imj.14000
  26. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091. https://doi.org/10.1200/JCO.2013.49.6968
  27. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. https://doi.org/10.1001/jama.2017.18718
  28. Attarian F, Taghizadeh-Hesary F, Fanipakdel A, Javadinia SA, Porouhan P, PeyroShabany B, Fazilat-Panah D. A systematic review and meta-analysis on the number of adjuvant temozolomide cycles in newly diagnosed glioblastoma. Front Oncol. 2021;11:779491. https://doi.org/10.3389/fonc.2021.779491
  29. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.  https://doi.org/10.1056/NEJMoa1308573
  30. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79(5):1487-1495. https://doi.org/10.1016/j.ijrobp.2009.12.061
  31. Cenciarini M, Valentino M, Belia S, Sforna L, Rosa P, Ronchetti S, D’Adamo MC, Pessia M. Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies. Front Mol Neurosci. 2019;12:65.  https://doi.org/10.3389/fnmol.2019.00065
  32. Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro Oncol. 2012;14(suppl 4):73-80.  https://doi.org/10.1093/neuonc/nos197
  33. Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, et al.; Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393(10172):678-688.  https://doi.org/10.1016/S0140-6736(18)31791-4
  34. Yuan B, Wang G, Tang X, Tong A, Zhou L. Immunotherapy of glioblastoma: recent advances and future prospects. Hum Vaccin Immunother. 2022;18(5):2055417. https://doi.org/10.1080/21645515.2022.2055417
  35. Ellsworth S, Ye X, Grossman SA. Clinical, radiographic, and pathologic findings in patients undergoing reoperation following radiation therapy and temozolomide for newly diagnosed glioblastoma. Am J Clin Oncol. 2017;40(3):219-222.  https://doi.org/10.1097/COC.0000000000000136
  36. De Bonis P, Fiorentino A, Anile C, Balducci M, Pompucci A, Chiesa S, Sica G, Lama G, Maira G, Mangiola A. The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. Clin Neurol Neurosurg. 2013;115(7):883-886.  https://doi.org/10.1016/j.clineuro.2012.08.030
  37. Mukherjee S, Wood J, Liaquat I, Stapleton SR, Martin AJ. Craniotomy for recurrent glioblastoma: is it justified? A comparative cohort study with outcomes over 10 years. Clin Neurol Neurosurg. 2020;188:105568. https://doi.org/10.1016/j.clineuro.2019.105568
  38. Barney C, Shukla G, Bhamidipati D, Palmer JD. Re-irradiation for recurrent glioblastoma multiforme. Chin Clin Oncol. 2017;6(4):36.  https://doi.org/10.21037/cco.2017.06.18
  39. Baehr A, Trog D, Oertel M, Welsch S, Kröger K, Grauer O, Haverkamp U, Eich HT. Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts. Strahlenther Onkol. 2020;196(5):457-464.  https://doi.org/10.1007/s00066-020-01585-0
  40. Knisely JPS, Fine HA. Reirradiation for recurrent glioblastoma: what we know and what we do not. J Clin Oncol. 2022:41(6):1183-1188. https://doi.org/10.1200/JCO.22.01785
  41. McBain C, Lawrie TA, Rogozińska E, Kernohan A, Robinson T, Jefferies S. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021;5(1):CD013579. https://doi.org/10.1002/14651858.CD013579.pub2
  42. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med. 2012;67(1):237-245.  https://doi.org/10.1002/mrm.23003
  43. Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, et al. Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine. Int J Mol Sci. 2017;18(5):995.  https://doi.org/10.3390/ijms18050995
  44. Gallego O. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 2015;22(4):273-281.  https://doi.org/10.3747/co.22.2436
  45. Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954-1963. https://doi.org/10.1056/NEJMoa1707358
  46. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011;117(23):5351-5358. https://doi.org/10.1002/cncr.26188
  47. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018;20(5):674-686.  https://doi.org/10.1093/neuonc/nox208
  48. McGranahan T, Therkelsen KE, Ahmad S, Nagpal S. Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol. 2019;20(3):24.  https://doi.org/10.1007/s11864-019-0619-4
  49. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477-486.  https://doi.org/10.1038/s41591-018-0337-7
  50. De Felice M, De Marinis P, Martin G, Bruscella S, De Bellis A, Poliero L, Turitto G. Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature. Eur Rev Med Pharmacol Sci. 2022;26(14):5008-5013. https://doi.org/10.26355/eurrev_202207_29287
  51. Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20(1):110-119.  https://doi.org/10.1016/S1470-2045(18)30675-2
  52. Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, et al. BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol. 2018;36(35):3477-3484. https://doi.org/10.1200/JCO.2018.78.9990
  53. Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA. Concurrent BRAF/MEK inhibitors in BRAF V600-mutant high-grade primary brain tumors. J Natl Compr Canc Netw. 2018;16(4):343-347.  https://doi.org/10.6004/jnccn.2017.7052
  54. Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7(22):33440-33450. https://doi.org/10.18632/oncotarget.7961
  55. Eckerdt FD, Bell JB, Gonzalez C, Oh MS, Perez RE, Mazewski C, Fischietti M, Goldman S, Nakano I, Platanias LC. Combined PI3Kα-mTOR targeting of glioma stem cells. Sci Rep. 2020;10(1):21873. https://doi.org/10.1038/s41598-020-78788-z
  56. Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, Zou Z, Li P, Guo Q, Ma L, He C, Huang S. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12(1):177.  https://doi.org/10.1038/s41467-020-20379-7
  57. Iqbal A, Eckerdt F, Bell J, Nakano I, Giles FJ, Cheng SY, Lulla RR, Goldman S, Platanias LC. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. Oncotarget. 2016;7(22):33192-33201. https://doi.org/10.18632/oncotarget.8899
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.